Skip to main content

Table 1 Baseline characteristics of patients in the ITT phase 2 and validation cohorts

From: Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial

  ITT Phase 2 ITT Validation
N = 301 N = 920
Geographic area—no. (%)
 Lombardia 136 (45.2%) 346 (37.6%)
 Veneto 65 (21.6%) 41 (4.5%)
 Emilia Romagna 37 (12.3%) 142 (15.4%)
 Other Northern regions 91 (9.9%)
 Center 39 (13.0%) 186 (20.2%)
 South and Islands 24 (8.0%) 114 (12.4%)
Age—no. (%)
  ≤ 60 122 (40.5%) 375 (40.8%)
 61–70 107 (35.5%) 263 (28.6%)
 71 +  72 (23.9%) 282 (30.7%)
Female sex—no. (%) 59 (19.6%) 200 (21.7%)
Ethnic group—no. (%)
 Caucasian 271 (97.1%) 853 (97.7%)
 Asiatic 3 (1.1%) 2 (0.2%)
 Other 5 (1.8%) 18 (2.1%)
 Unknown 22 47
Body mass index—no. (%)
 Underweight/normal (< 25) 75 (28.8%) 192 (26.9%)
 Overweight/obese (25 +) 185 (71.2%) 521 (73.1%)
 Unknown 41 207
Previous/actual smoker—No. (%) 51 (22.2%) 214 (29.2%)
 Unknown 71 188
Antiflu 2019 vaccination—No. (%) 54 (25.0%) 121 (20.3%)
 Unknown 85 325
Initial respiratory support—No. (%)
 Oxygen supplementation 146 (48.5%) 468 (50.9%)
 NIMV 106 (35.2%) 359 (39.0%)
 IMV 49 (16.3%) 93 (10.1%)
PaO2/FiO2 ratio—median (IQR) 136 (93,198) 154 (103,218)
PaO2/FiO2 ratio—No. (%)   
  < 100 55 (32.4%) 129 (24.1%)
 101–200 76 (44.7%) 244 (45.5%)
 201–300 32 (18.8%) 116 (21.6%)
  > 300 7 (4.1%) 47 (8.8%)
 Missing or not tested 131 384
Comorbidities (mild or worse)—No. (%)   
 Heart disease 62 (21.6%) 150 (18.1%)
 Hypertension 147 (51.2%) 389 (47.0%)
 Diabetes 34 (11.8%) 138 (16.7%)
 Unknown 14 93
Concurrent treatment, no. (%)   
 Antiretroviral 180 (63.1%) 576 (67.6%)
 Hydroxy-chloroquine 207 (72.6%) 651 (76.4%)
 Antibiotics 118 (41.4%) 443 (52.0%)
 Steroids 62 (21.8%) 296 (34.7%)
 LMW heparin 66 (23.2%) 175 (20.5%)
 Unknown 16 68
C-reactive protein—median (IQR) 37.6 (14.7, 120.0) 36.3 (13.7, 137.0)
 Missing or not tested 181 255